A Single-blind, Placebo Controlled Sleep Laboratory Study of the Acute Effects of Aplindore in Restless Legs Syndrome.
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2011
At a glance
- Drugs Aplindore (Primary)
- Indications Restless legs syndrome
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Neurogen Corporation
- 10 Aug 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 24 Oct 2008 Positive top-line results announced by Neurogen Corporation.
- 11 Mar 2008 Status changed from initiated to recruiting. Updated from ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History